latest update:
[TrialBase DB]

trial summary · NCT07814105

[11C]Metomidate PET-CT vs Usual Care for People With Primary Aldosteronism: a Proof-of-concept Study

Trial record from the TrialBase DB dataset, status RECRUITING, condition Primary Aldosteronism, sponsored by Chinese University of Hong Kong. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07814105phase —enrollment 32start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this randomised open-label controlled study is to compare the biochemical and clinical responses following \[11C\]Metomidate-PET CT(MTO-PET) versus usual care with adrenal venous sampling as first lateralisation strategy in people with biochemically confirmed primary aldosteronism(PA). The main question it aims to answer is: what is the proportion of people who achieved complete or partial clinical success among those who underwent PA treatment?

Source record: https://clinicaltrials.gov/study/NCT07814105

Facts

registry idNCT07814105
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionPrimary Aldosteronism
sponsorChinese University of Hong Kong
sponsor classOTHER
enrollment32
start date2026-11-01
primary completion2030-09
completion2030-09
results postednot reported

Conditions

  • Primary Aldosteronism

Interventions

  • [11C] Metomidate PETCT
  • Adrenal Venous Sampling

Countries

  • Hong Kong

Intervention types: PROCEDURE

Work with this record